Improving access to novel heart failure agents through a defined multidisciplinary pathway

Novel emerging heart failure medication therapies, particularly sacubitril/valsartan and corlanor, have shown promise in improving patient outcomes and decreasing hospitalizations and death in our heart failure population. Patient access and prescription coverage for these novel heart failure medication therapies can be a huge barrier for allowing heart failure patients to have access to these new medications. Recognizing this barrier, our medical center has developed a multidisciplinary pathway to help guide our institution in helping enable our patients to having access to the most cutting edge guideline-directed medical therapy though a defined pathway.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research